Across TCGA pan-cancer cohorts, HBM mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HBM data layer compared with 15 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher HBM mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HBM expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

UCEC, CCRCC, and PDAC are the cancer types where HBM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	III,IV	0.190	1.000	.010	12	view →
CCRCC	DFS	Median	III,IV	0.874	0.429	.021	5	view →
PDAC	OS	Median	All	0.296	0.572	.017	5	view →
LUAD	OS	Median	All	0.908	0.772	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: HBM tumor-vs-normal RNA expression · all HBM data types